There’s a lot of converging data right now to inform what second-line treatment we’re using when patients progress on either nivolumab plus ipilimumab, adjuvant pembrolizumab, or pembrolizumab plus axitinib. You have the Len-Cabo study, our study, that showed improved efficacy with lenvatinib plus everolimus, but some trade-off with worsening body composition and tolerability with that combination compared to cabozantinib...
There’s a lot of converging data right now to inform what second-line treatment we’re using when patients progress on either nivolumab plus ipilimumab, adjuvant pembrolizumab, or pembrolizumab plus axitinib. You have the Len-Cabo study, our study, that showed improved efficacy with lenvatinib plus everolimus, but some trade-off with worsening body composition and tolerability with that combination compared to cabozantinib. Additionally, you have the KEYNOTE-361 study is not mentioned but another study is the LightSpark 11 study that is not the actual name but is actually called the KEYNOTE-581/LEAP-011 or possibly another, that showed improved progression-free survival and objective response rate with lenvatinib plus belzutifan when compared to cabozantinib. So you now have three options to choose from. And I think my takeaway from our studies is that if you’re wanting to prioritize efficacy, which you likely are in the majority of patients that you’re treating, you probably should go with the lenvatinib-based doublet for those patients. But for those patients, maybe older patients, frail patients, patients who’ve had a lot of toxicity with prior therapies, where you’re wanting to prioritize tolerability, our data argues, the quality of life data from the actual study argue that cabozantinib is the better choice in that situation.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
